AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17088680 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide before stress scan
Number of subjects: 95
Study 17088680 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide before rest scan
Number of subjects: 95
Study 17088680 — intervention group
Group type: COMPARATOR
Intervention: Control group (no metoclopramide)
Number of subjects: 95
Study 17088680 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (both stress and rest)
Number of subjects: 95
Study 15510237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg once daily
Number of subjects: 4325
Study 15510237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4325
Study 12528546 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 96
Study 12528546 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 96
Study 9024172 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg valsartan
Number of subjects: 6
Study 9024172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8302672 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate 25 mg/kg
Number of subjects: 20
Study 8302672 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate 50 mg/kg
Number of subjects: 20
Study 8302672 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate 70 mg/kg
Number of subjects: 20
Study 8302672 — intervention group
Group type: COMPARATOR
Intervention: Chloral hydrate doses (25 mg/kg vs 70 mg/kg)
Number of subjects: 20
Study 8302672 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG amplitude
Number of subjects: 20
Study 3119689 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (inhalant corticosteroid)
Number of subjects: 13
Study 3119689 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (single-dose pretreatment)
Number of subjects: 13
Study 3119689 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (single-dose pretreatment, beta 2-agonist)
Number of subjects: 13
Study 31882009 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity (10,000 steps walking, 5-8 METs) with hypocaloric diet
Number of subjects: 117
Study 31882009 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intense physical activity (at least 70% of VO2max, >8 METs) with hypocaloric diet
Number of subjects: 117
Study 31882009 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet only (no physical activity prescribed)
Number of subjects: 117
Study 28359166 — intervention group
Group type: EXPERIMENTAL
Intervention: Having an exercise partner
Number of subjects: 436
Study 28359166 — intervention group
Group type: EXPERIMENTAL
Intervention: Help with household duties
Number of subjects: 436
Study 28359166 — intervention group
Group type: EXPERIMENTAL
Intervention: Being 'very much' satisfied with support
Number of subjects: 436
Study 28359166 — intervention group
Group type: EXPERIMENTAL
Intervention: Naming >2 supporters
Number of subjects: 436
Study 26656783 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 0
Study 24216399 — intervention group
Group type: EXPERIMENTAL
Intervention: Face Mask Removal (FMR)
Number of subjects: 22
Study 24216399 — intervention group
Group type: COMPARATOR
Intervention: Helmet Removal (HR)
Number of subjects: 22
Study 24216399 — intervention group
Group type: COMPARATOR
Intervention: Riddell Revolution IQ (RIQ) with Helmet Removal (HR)
Number of subjects: 22
Study 24216399 — intervention group
Group type: COMPARATOR
Intervention: VSR4 with Helmet Removal (HR)
Number of subjects: 22
Study 24216399 — intervention group
Group type: COMPARATOR
Intervention: Inflated helmets (regardless of helmet type)
Number of subjects: 22
Study 24216399 — intervention group
Group type: COMPARATOR
Intervention: Deflated helmets (regardless of helmet type)
Number of subjects: 22
Study 22575165 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotamix IgY
Number of subjects: 54
Study 22575165 — intervention group
Group type: COMPARATOR
Intervention: Placebo IgY
Number of subjects: 54
Study 20153700 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastibell® circumcision (PD)
Number of subjects: 125
Study 20153700 — intervention group
Group type: COMPARATOR
Intervention: Dissection circumcision (DC)
Number of subjects: 125
Study 17957213 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 30
Study 17957213 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo nasal spray
Number of subjects: 30
Study 15716253 — intervention group
Group type: EXPERIMENTAL
Intervention: Opening wedge osteotomy
Number of subjects: 35
Study 12417369 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin intervention regimen (folic acid, vitamins B(6) and B(12))
Number of subjects: 3688
Study 12417369 — intervention group
Group type: COMPARATOR
Intervention: Low-dose vitamin intervention regimen (folic acid, vitamins B(6) and B(12))
Number of subjects: 3688
Study 10740521 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-neon diode laser (1.4 mw, 670 nm) for 30 seconds (fluence = 0.34 J/cm2)
Number of subjects: 58
Study 10740521 — intervention group
Group type: COMPARATOR
Intervention: Control incisions (not specified)
Number of subjects: 58
Study 7742759 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin prophylaxis (500 mg x 3 peri-operatively)
Number of subjects: 40
Study 7742759 — intervention group
Group type: COMPARATOR
Intervention: No vancomycin prophylaxis
Number of subjects: 40
Study 7742759 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin prophylaxis
Number of subjects: 40
Study 2045037 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 2 g single oral dose
Number of subjects: 75
Study 2045037 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 400 mg vaginal tablet (2 x 1) for five consecutive days
Number of subjects: 75
Study 7049600 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery + radiotherapy + CCNU, vincristine
Number of subjects: 0
Study 7049600 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery + radiotherapy + CCNU, vincristine, procarbazine
Number of subjects: 0
Study 30006862 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group P)
Number of subjects: 50
Study 30006862 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (group S)
Number of subjects: 50
Study 28389435 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle suprapubic cutaneous stimulation (Quick-Wee method)
Number of subjects: 344
Study 25841136 — intervention group
Group type: EXPERIMENTAL
Intervention: 2500 UFH units
Number of subjects: 731
Study 25841136 — intervention group
Group type: COMPARATOR
Intervention: 5000 UFH units
Number of subjects: 731
Study 25841136 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled population with 2500 UFH units
Number of subjects: 731
Study 25841136 — intervention group
Group type: COMPARATOR
Intervention: Pooled population with 5000 UFH units
Number of subjects: 731
Study 25841136 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean UFH dose difference
Number of subjects: 731
Study 24373830 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-system (COS) PIVCs
Number of subjects: 1199
Study 24373830 — intervention group
Group type: COMPARATOR
Intervention: Open-system (MOS) PIVCs
Number of subjects: 1199
Study 21067893 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior capsule relaxing incisions with neodymium:YAG laser
Number of subjects: 84
Study 21067893 — intervention group
Group type: COMPARATOR
Intervention: No capsulotomy (control group)
Number of subjects: 84
Study 19807985 — intervention group
Group type: EXPERIMENTAL
Intervention: Original azelastine nasal spray, 2 sprays/nostril b.i.d.
Number of subjects: 835
Study 19807985 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformulated azelastine nasal spray, 2 sprays/nostril b.i.d.
Number of subjects: 835
Study 19807985 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 2 sprays/nostril b.i.d.
Number of subjects: 835
Study 19807985 — intervention group
Group type: EXPERIMENTAL
Intervention: Original azelastine nasal spray, 1 spray/nostril b.i.d.
Number of subjects: 835
Study 19807985 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformulated azelastine, 1 spray/nostril b.i.d.
Number of subjects: 835
Study 17702725 — intervention group
Group type: EXPERIMENTAL
Intervention: B cell‐driven treatment
Number of subjects: 36
Study 17702725 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol of four weekly doses of 375 mg/m2
Number of subjects: 36
Study 15500669 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% SLS solution applied to scalp
Number of subjects: 10
Study 15500669 — intervention group
Group type: COMPARATOR
Intervention: 20% SLS solution applied to back
Number of subjects: 10
Study 15500669 — intervention group
Group type: COMPARATOR
Intervention: 20% SLS solution applied to arm
Number of subjects: 10
Study 11413660 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric feeding
Number of subjects: 25
Study 11413660 — intervention group
Group type: COMPARATOR
Intervention: Duodenal feeding
Number of subjects: 25
Study 9759942 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine effervescent formulation
Number of subjects: 98
Study 9759942 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine standard formulation
Number of subjects: 98
Study 7995270 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study 7995270 — intervention group
Group type: EXPERIMENTAL
Intervention: Other ACE inhibitors
Number of subjects: 0
Study 2899582 — intervention group
Group type: EXPERIMENTAL
Intervention: Detergent containing chlorhexidine (CHX+)
Number of subjects: 2813
Study 2899582 — intervention group
Group type: COMPARATOR
Intervention: Detergent without chlorhexidine (CHX-)
Number of subjects: 2813
Study 30507231 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive message about PBS users
Number of subjects: 130
Study 30507231 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative message about non-PBS users
Number of subjects: 130
Study 30507231 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130
Study 27599226 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent engagement package
Number of subjects: 122
Study 27599226 — intervention group
Group type: COMPARATOR
Intervention: Brochure plus nonengagement survey interview
Number of subjects: 122
Study 24479853 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure education program (intervention)
Number of subjects: 60
Study 22282300 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk with 250 mg calcium daily
Number of subjects: 141
Study 22282300 — intervention group
Group type: EXPERIMENTAL
Intervention: Soymilk with 250 mg calcium daily
Number of subjects: 141
Study 22282300 — intervention group
Group type: COMPARATOR
Intervention: Neither milk nor soymilk (Control)
Number of subjects: 141
Study 20627524 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal cooling for 1h
Number of subjects: 84
Study 18355422 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg plus 20 mL antacid suspension taken simultaneously
Number of subjects: 14
Study 18355422 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg plus 20 mL antacid suspension taken 2 h after rosuvastatin
Number of subjects: 14
Study 18355422 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 40 mg alone
Number of subjects: 14
Study 16155164 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiography (CE MRA)
Number of subjects: 40
Study 16155164 — intervention group
Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 40
Study 12848771 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg pseudoephedrine hydrochloride
Number of subjects: 8
Study 12848771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10574493 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitreon left intravitreally for 4 weeks (Group B)
Number of subjects: 105
Study 10574493 — intervention group
Group type: COMPARATOR
Intervention: Vitreon removed at the end of operation (Group A)
Number of subjects: 105
Study 8690562 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase therapy
Number of subjects: 0
Study 1934252 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone plus cytarabine (3‐plus 7‐day schedule for induction, 2‐plus 5‐day schedule for post-induction)
Number of subjects: 44
Study 1934252 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin plus cytarabine (control arm)
Number of subjects: 44
Study 31082916 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection of the primary tumor followed by systemic therapy (Arm A)
Number of subjects: 90
Study 31082916 — intervention group
Group type: COMPARATOR
Intervention: Primary systemic therapy (Arm B)
Number of subjects: 90
Study 30027600 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal test and treat strategy (UTT)
Number of subjects: 0
Study 30027600 — intervention group
Group type: COMPARATOR
Intervention: In-migrants and out-migrants
Number of subjects: 0
Study 30027600 — intervention group
Group type: COMPARATOR
Intervention: HIV seroconversions
Number of subjects: 0
Study 29231360 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with western medicine (needle‐medicine group)
Number of subjects: 90
Study 29231360 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture alone (acupuncture group)
Number of subjects: 90
Study 29231360 — intervention group
Group type: COMPARATOR
Intervention: Western medicine alone (medicine group)
Number of subjects: 90
Study 25045910 — intervention group
Group type: EXPERIMENTAL
Intervention: BCT plus 12-step-oriented IBT
Number of subjects: 105
Study 25045910 — intervention group
Group type: EXPERIMENTAL
Intervention: BCT
Number of subjects: 105
Study 25045910 — intervention group
Group type: COMPARATOR
Intervention: BCT and IBT
Number of subjects: 105
Study 22050786 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg + Metformin 1000 mg b.i.d.
Number of subjects: 104
Study 22050786 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg + Metformin 500 mg b.i.d.
Number of subjects: 104
Study 22050786 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg b.i.d.
Number of subjects: 104
Study 22050786 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg b.i.d.
Number of subjects: 104
Study 22050786 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg q.d.
Number of subjects: 104
Study 22050786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 22050786 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Sitagliptin + Metformin)
Number of subjects: 104
Study 20646032 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory comprehensive educational project on disability
Number of subjects: 1509
Study 20646032 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1509
Study 17557987 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise, 60 min/d, 6 days/wk
Number of subjects: 202
Study 15149480 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage intervention (details not specified)
Number of subjects: 400
Study 15149480 — intervention group
Group type: EXPERIMENTAL
Intervention: Health insurance during follow-up
Number of subjects: 400
Study 15149480 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for abstinence by family or friends
Number of subjects: 400
Study 15149480 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent visit to a medical clinic or physician
Number of subjects: 400
Study 15149480 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent mental health or addictions treatment utilization
Number of subjects: 400
Study 15149480 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status
Number of subjects: 400
Study 12068843 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 17000
Study 12068843 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase + enoxaparin
Number of subjects: 17000
Study 12068843 — intervention group
Group type: COMPARATOR
Intervention: Alteplase + enoxaparin
Number of subjects: 17000
Study 12068843 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 17000
Study 9585285 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine (3 microg/kg)
Number of subjects: 50
Study 9585285 — intervention group
Group type: COMPARATOR
Intervention: Oral temazepam (10-20 mg)
Number of subjects: 50
Study 9098247 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery in both eyes
Number of subjects: 772
Study 9098247 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery in one eye
Number of subjects: 772
Study 2614821 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training
Number of subjects: 36
Study 2614821 — intervention group
Group type: COMPARATOR
Intervention: Simple instructions (Control)
Number of subjects: 36
Study 405730 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg sodium aurothiomalate weekly
Number of subjects: 60
Study 405730 — intervention group
Group type: COMPARATOR
Intervention: 50 mg sodium aurothiomalate weekly
Number of subjects: 60
Study 31390330 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory flow accelerator (EFA)
Number of subjects: 20
Study 31390330 — intervention group
Group type: COMPARATOR
Intervention: Bubble‐PEP (BP)
Number of subjects: 20
Study 28159194 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg
Number of subjects: 429
Study 28159194 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 600 mg
Number of subjects: 429
Study 28159194 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (after clopidogrel)
Number of subjects: 429
Study 28159194 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (maintenance)
Number of subjects: 429
Study 28159194 — intervention group
Group type: EXPERIMENTAL
Intervention: Thienopyridine-naïve patients loaded with prasugrel
Number of subjects: 429
Study 28159194 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment of HTPR patients
Number of subjects: 429
Study 28159194 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall clinical outcomes
Number of subjects: 429
Study 25747308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactation support intervention (met with an International Board‐Certified Lactation Consultant in hospital and 1‐3 times post discharge)
Number of subjects: 99
Study 25747308 — intervention group
Group type: COMPARATOR
Intervention: Standard care for jaundice (control group)
Number of subjects: 99
Study 23104974 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly team meetings through video or phone conferencing
Number of subjects: 249
Study 23104974 — intervention group
Group type: COMPARATOR
Intervention: Usual care from the hospice
Number of subjects: 249
Study 21699697 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ40 (extended five-day treatment at 40 mg/kg)
Number of subjects: 142
Study 21699697 — intervention group
Group type: COMPARATOR
Intervention: CQ25 (standard three-day treatment at 25 mg/kg)
Number of subjects: 142
Study 19196886 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (10 mg o.d.)
Number of subjects: 18
Study 19196886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (10 mg/day)
Number of subjects: 18
Study 19196886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril plus Tadalafil
Number of subjects: 18
Study 19196886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 19196886 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 18
Study 16234834 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleotide-supplemented formula (33.5 mg/l)
Number of subjects: 220
Study 16234834 — intervention group
Group type: COMPARATOR
Intervention: Control formula (10 mg/l NT)
Number of subjects: 220
Study 15144934 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 11419885 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Angiography (CA)
Number of subjects: 248
Study 11419885 — intervention group
Group type: COMPARATOR
Intervention: Exercise Treadmill Testing (ETT)
Number of subjects: 248
Study 9321530 — intervention group
Group type: EXPERIMENTAL
Intervention: cA2 (5 mg/kg)
Number of subjects: 108
Study 9321530 — intervention group
Group type: EXPERIMENTAL
Intervention: cA2 (10 mg/kg)
Number of subjects: 108
Study 9321530 — intervention group
Group type: EXPERIMENTAL
Intervention: cA2 (20 mg/kg)
Number of subjects: 108
Study 9321530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 9321530 — intervention group
Group type: EXPERIMENTAL
Intervention: cA2
Number of subjects: 108
Study 8404750 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) 1.0 g twice daily for 6 weeks, followed by 1.5 g twice daily for 6 weeks
Number of subjects: 24
Study 8404750 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) 2 g daily
Number of subjects: 24
Study 8404750 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) 3 g daily
Number of subjects: 24
Study 8404750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3081918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg b.d.)
Number of subjects: 6
Study 3081918 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg b.d.)
Number of subjects: 6
Study 3081918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31432705 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in second-line setting with PD-L1 ≥1% (KEYNOTE-010)
Number of subjects: 5
Study 31432705 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in first-line setting with PD-L1 ≥50% (KEYNOTE-024 and KEYNOTE-042)
Number of subjects: 5
Study 31432705 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in first-line setting in combination with platinum doublets, any expression of PD-L1 (KEYNOTE-189 and KEYNOTE-407)
Number of subjects: 5
Study 30244214 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual ERS plus web-based behavioural support
Number of subjects: 413
Study 30244214 — intervention group
Group type: COMPARATOR
Intervention: Usual ERS alone (control)
Number of subjects: 413
Study 27299709 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg once daily
Number of subjects: 0